Protection of mice against EMC virus infection by poly C and poly I has already been distinguished from interferon mediated protection in several ways. Transfer of serum from EMC virus infected and poly C or poly I treated mice to donor mice that were then infected shows that the anti-viral effect of the single-stranded polynucleotides is not due to boosting interferon produced by infection itself in the way that interferon can be' primed' in vitro. Mice surviving infections of more than I x LD100 as a result of poly C or poly I treatment show no protection against re-infection 15 days after the first infection, indicating no long-term stimulation of immune responses to the virus. Mice treated with an immunosuppressive regime of cytosine arabinoside can be protected against EMC virus infection with poly C and poly I treatment and athymic 'nude' mice can also be protected. The possibility of IgM stimulation by poly C and poly I seems unlikely from experiments in which serum was transferred from mice treated with the polynucleotides and an inactivated EMC 'vaccine' to recipient mice which were then chalIenged with infectious virus.
INTRODUCTION
We have found that poly I and poly C have anti-viral activity in mice against infection by encephalomyocarditis (EMC) virus and Semliki Forest virus (SFV; Stebbing, Grantham & Carey, 1976) and that sequential administration of these polynucleotides shows a synergistic effect (Stebbing & Grantham, 1976) and in all these cases protection occurs without induction of circulating interferon. We have suggested that poly C and poly I, because they mimic the poly C tract in the virion RNA (Porter, Carey & Fellner, 1974) or its complement in the minus strand, could act as competitive inhibitors of virus replication (Stebbing et al. I976) . However, other mechanisms seem possible such as 'priming' by poly I or poly C for interferon induction by virus infection itself and specific stimulation of the immune systems of the mouse by the polynucleotides. 'Priming' has to date only been reported for in vitro interferon induction by poly I: C (Margolis, Oie & Levy, I972) and the single-stranded polynucleotides have not been reported as effective. Nevertheless EMC infection is known to elicit production of interferon, although this response is not sufficient to protect mice (Jullien, I974) . Moreover, the adjuvant activity of double-stranded polynucleotides has not been demonstrated for poly I or poly C (Schmidtke & Johnson, I97~) .
We report here experiments demonstrating that these possible mechanisms are not involved in the anti-viral activity of poly I or poly C against EMC in mice. However, treatment of mice with various materials indicates that macrophages are involved in the antivirus effects of poly I and poly C and that these polynucleotides probably have an effect on virus replication and do not simply stimulate direct clearance of virus particles or complement mediated clearance of immune complexes by macrophages.
METHODS
Virus. Encephalomyocarditis virus (EMC) was grown and stored as previously described (Stebbing et al. I976 ). An EMC 'vaccine' was prepared by incubating virus stocks at high titre (> io 5 LD100/ml) at 37 °C for 7 days in the presence of o.I ~ formalin. This material was then stored at -2o °C and o. I ml of dilutions of up to lo -3 of this stock gave significant protection against a challenge of 1o x LD100 I4 days later.
Chemicals. Poly C, poly I and poly I: C were from P-L Biochemicals and obtained through International Enzymes Ltd., Windsor, Berks., U.K. The single-stranded polynucleotides were dissolved in HBS (0"89 ~ (w/v) NaCI, Io mM-HEPES, pH 7"5) and poly I:C was dissolved in water. The polynucleotides were injected intravenously into one of the lateral tail veins of mice in a volume of o.r ml, unless otherwise stated. Virus and vaccine stocks were also diluted in HBS and o-~ ml injected intraperitoneally.
Cytosine arabinoside HC1 was obtained from Sigma Chemical Co.; Pertussis was from Burroughs Wellcome. Wheat starch from Energen Food Co. Ltd was made up in HBS and heated at too °C for 5 min before use. Silica (Dorentrup I2) was a gift from Dr A. C.
Allison.
Mice. Female LACA mice were obtained from Bantin and Kingham Ltd., Hull, U.K. 'Nude' mice, bred on a C3H background were obtained from Anglia Laboratory Animals, Alconbury, Huntingdon, U.K. All mice used were between 6 and Io weeks old and weighed between I8 and 24 g. Mice were maintained at 22 °C with unlimited access to water and standard rat and mouse breeding diet from Grain Harvesters Ltd., Wingham, Kent, U.K. Serum was obtained from clotted blood collected by cardiac puncture after killing mice with excess carbon dioxide. About I ml blood was obtained per mouse and yielded 0"4 to o.6 ml serum.
Statistical method~. The survival time (t) of mice in hours was obtained from records prepared twice daily. An average survival time for a group of mice was obtained by calculating the mean of the reciprocals of the survival times taking the reciprocal of survivors to be zero and multiplying this mean by Ioo. These calculations are carried out on the data at I5 days post-infection after which time no further deaths occur (Stebbing et aL 1976) and the values obtained are designated as values of lit x io 2. Since mice infected with more 
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Investigation of interferon 'priming' in vivo by poly I and poly C
While we find that poly I and poly C alone do not induce detectable circulating interferon in mice (Stebbing et aL I976) , it is arguable that they could augment interferon produced by EMC infection to a level at which it is protective, in the same manner as interferon 'priming' of low doses of inducers in tissue-cultures (Margolis et al. I972) . This hypothesis is directly testable by examining the anti-viral activity of serum from infected mice that were also treated with poly I or poly C. We chose to treat the mice with poly I or poly C 6 h before infection since this time gives maximum protection (Stebbing et aL ~976). We examined serum obtained 2, 4 and I6 h after infection from mice treated in this way and the results, shown in Table IA , indicate no protection by the serum at any of these times. However, we were able to protect mice against EMC infection with serum obtained 4 h after donor mice had been treated with 6o/zg poly I: C (Table I B) . To minimize the effect of infectious virus in the serum of the donor animals we centrifuged out virus particles N. STEBBING, C. A. GRANTHAM AND F. KAMINSKI Asterisks indicate significance levels (see Methods). 1" Number of mice per group = 2o. Amount of poly I:C injected intravenously at -I6h = Io#g. Amount poly C or poly I injected intravenously at -24 h = 400 #g.
:~ X2~n,. = logrank comparisons with infected controls. X2x:c = logrank comparisons with poly I:C controls.
before administering the serum to the recipient mice and to maximize the protective effect we used serum from two donor mice for each recipient mouse and this enabled us to administer 1 ml of the serum to each recipient mouse.
We also investigated the possibility that poly C and poly I could prime induction of interferon by poly I:C. Ten/zg poly I:C, administered intravenously 16 h before infection with about Io x LD100 EMC, was found to give partial protection of mice, i.e. about 20 ~oo of the mice survived the infection and the other mice showed a delay in the mean time of death of about 48 h. The direct anti-viral effect of poly I or poly C alone is not as great 24 h before infection as it is 6 h before infection (Stebbing et al. t976) . We therefore investigated the effect of intravenous administration of 4oo/zg poly I or 4o0 #g poly C 2 4 h before infection on the degree of protection afforded by Io ¢tg poly I: C I6 h before infection. The results, in Table 2 , show that treatment with poly C or poly I and poly I: C does not provide significantly greater protection than poly I:C alone. Indeed, at a virus dose of I x LD100, the protection afforded by poly I:C alone was not exceeded by the combined treatments. Moreover, the only combined treatment with a significant difference from the poly I: C control (poly I and poly I:C at I × LD100 virus, X ~ = 4" 15*) shows less protection (~[t x io 3 = o'53, which is greater than that of the control = o'33). We have also found no enhancement of the protective effect of Io/zg poly I: C given I6 h before infection when poly C or poly I was given 40 or 52 h before infection.
We conclude that 'priming' by poly I or poly C of interferon induction by poly I: C or by EMC infection does not occur to any significant extent and certainly cannot provide an explanation for protection of mice by poly I or poly C treatments.
Investigation of specific immune stimulation by poly I and poly C
If stimulation of an immune response were capable of protecting mice against EMC infection the response must be rapid and to test whether such a response is possible we examined the effect of adding to doses of I and Io × LDao0 EMC, increasing amounts of a non-infectious EMC 'vaccine'. We found that as the dose of 'vaccine' increased the mice lived longer (lit x Io 2 values decreased) and almost 50 ~ of the mice survived when I x LD10o infective virus was mixed with a 'vaccine' dose equivalent to ~ o s x LDloo before inactivation. This was the only dose of vaccine which gave significant protection against so x LD100. The mice surviving I5 days after infection were re-infected with 5 x LDa0 o EMC and found to be completely protected, indicating that immunity had been conferred by addition of inactive virus to the first infecting dose of EMC. From these observations we conclude that it is possible for EMC antigens administered at the time of infection to stimulate a protective immune response.
On several occasions we have re-infected the surviving mice from a group that were infected by virus doses in excess of I x LDa00 and also treated with poly I or poly C. In all cases we have found such mice to be just as susceptible to re-infection as a parallel group of previously untreated and uninfected mice. We conclude that there cannot be significant development of ]gG or cell-mediated immunity against EMC in mice that have been protected by poly I or poly C treatment.
However, stimulation of production of specific IgM by poly I or poly C, to a level which could be protective, is not eliminated by these re-infection experiments. IgM reaches a peak between 3 and 4 days after antigen challenge in mice and could therefore be boosted to protect mice against EMC without showing any protection against re-infection 15 days after the first infection. We therefore tested serum from mice 3 days after 'vaccine' treatment and looked for an increase in the ability of this serum to protect other mice when the donor mice had also been treated with poly C 6 h before the 'vaccine' treatment. The dose of the EMC 'vaccine' used was one that just gave significant protection against challenge with 5 x LD10 o EMC I5 days after vaccination and corresponded to a titre of ~o 4 x LDlo0 prior to inactivation. Serum was obtained from groups of 50 mice 3 days after they had been treated with the 'vaccine', or 4oo/zg poly C, or 'vaccine' and 4oo #g poly C (Table 3) . These sera were administered intraperitoneally to mice which were then challenged ½ h later with 5 × LD~0o EMC. Serum was also obtained from two additional groups of mice which had been treated with poly C and the 'vaccine'. One of these batches of serum was made o. ~ mM with 2-mercaptoethanol and incubated for I h at 37 °C to destroy IgM prior to administration to mice. The other batch was absorbed with ~ ml of the undiluted stock 'vaccine' at 4 °C for 3o min before removing any virus particles or immune complexes that might be present by centrifuging at 55ooo rev/miu for 9 ° min in the Ti-5o rotor of a Beckman L 25o centrifuge. The effect of the various sera on survival of mice is shown in Table 3 A, from which it is clear that serum from poly C-treated mice does not give enhanced protection to the recipient mice. Logrank X 2 comparisons of the groups receiving serum from the variously treated mice showed no significant differences from the group given serum from untreated mice (largest value of X z for comparisons with first group in Table 3 A rather than infected control = 2-42 ).
Although the amount of serum administered to the mice was large we also examined the effect of treating mice with the same dose of serum daily for 4 days after infection. The results, in Table 3 B, also show no protection against infection by the serum obtained 3 days after poly I or poly C treatment and vaccination of the donor mice. Since the polynucleotide treatment 6 h before 'vaccine' treatment could cause non-specific release of specific antibodies from macrophages we also examined the ability of serum obtained 24 h after the 'vaccine' treatment to protect other mice but no protection was observed (see Table 3 C).
Our ability to confer immunoglobulin mediated protection by transfer of serum to other mice could be questioned. We have therefore compared protection by vaccination 4 days and 14 days before infection with the degree of protection afforded by serum transferred 3 VIR ~2 t Polynucleotides, 4oo #g per donor mouse, injected intraperitoneally 6 h before intraperitoneal injection of a 'vaccine' dose which before inactivation titred at iOx LD100. Number of mice in the control groups: A=2o, B= Io, C= IO.
$ n = number of mice per group. § Xmin~. = logrank comparisons with the infected control groups. ]1 ME = 2-mercaptoethanol. at these times to other mice that were then infected ½ h later. The results, in Table 4 , show that the degree of protection of serum treated animals is as good as in the vaccinated controls.
The effect of immunosuppression
Cytosine arabinoside is known to be immunosuppressive (Connors, 1973 ) and has been shown to prolong survival of skin and kidney allografts (Beyer & Friedman, 1975) . Treatment of LACA mice in the same regime as used by Beyer & Friedman, I975 (4 rng cytosine arabinoside every day for 4 days) either before or after infection was found to have no effect on survival of mice (Table 5 ) and no toxic deaths occurred in a cytosine arabinoside treated control group within 4 weeks of treatment. Moreover, treatment of mice with cytosine arabinoside before or after infection was found to have no effect on protection by poly I or poly C administered 6 h before infection ( Anti-viral mechanism of poly I and poly C 3I t Virus dose in both experiments was 5 × LD100. Cytosine arabinoside treatment was 4 mg intraperitoneally daily for 4 days before or after the day of infection, as indicated.
§ Amount of poly C or poly I injected intravenously 6 h before infection = 40o #g. Number of mice per group was IO for the poly C treatment experiment and its controls and 20 for the poly I treatment experiment and its controls.
Jl X2~,t. = logrank comparisons with the infected control. X2~ = logrank comparisons with the polynucleotide treated control. Values of lit × ]o 2 with X 2 comparisons shown in parentheses.
of T-cell-mediated protection by poly C or poly I was obtained by examining protection of 'nude' mice by the polynucleotides. One experiment with 'nude' mice showed that poly C and poly I both gave significant protection against infection with 5 × LD100 EMC when the polynucleotides were administered intraperitoneally 6 h before infection. However, the degree of protection was much less than with LACA mice. We therefore examined the protective effect of poly C 6 h before infection of nude mice and their hairy litter mates and found onlya small although significant degree of protection in both types of mice. These results indicate that nude mice can be protected against EMC virus infection by poly C and that the small degree of protection is a feature of the genetic background of the' nude' mice and not due to the lack of a thymus.
The involvement of macrophages in protection by poly C and poly I
Silica is known to be specifically cytotoxic for macrophages in mice (Allison, Harington & Birbeck, 1966) and 25 mg of 'Dorentrup I 2' silica administered intraperitoneally has been shown to render adult mice susceptible to Coxsackie B-3 infection (Rager-Zisman & Allison, I973). The data in Table 6 show that this level of silica given intraperitoneally completely abolishes protection by poly C or poly I against EMC infection and that 5 mg of the silica given intravenously is equally effective. These observations indicate that macrophages are involved in the protection conferred by poly C and poly I and that the population of macrophages involved are not merely those in the vicinity of virus administration.
Pertussis (o.I ml intraperitoneally) and starch (up to Ioo/zg intraperitoneally) cause a marked increase in peritoneal macrophages within 3 days but treatment of mice with Pertussis or starch 3 days before infection was not found to increase the protective effect of poly C or poly I given by the intravenous or intraperitoneal routes 6 h before infection. These observations indicate that the population of macrophages important for protection by poly C or poly I are not merely the mobile macrophages recruited to the peritoneal cavity as a result of irritation by the Pertussis or starch treatment.
3-2 N. STEBBING~ C. A. GRANTHAM AND F. KAMINSKI i Number of mice per group = 2o. Virus dose = Io x LDao0. :~ Silica, 25 mg in 0.2 ml i.p. or 5 mg in o-I ml i.v., as indicated 8 h before infection. § Polynucleotides, 4oo #g per mouse, administered as indicated 6 h before infection, i.p. = intraperitoneal, i.v. = intravenous.
I/ X~iTl~. = logrank comparisons with infected controls. ' vaccine ' control control 0"64 0"87 i Number of mice per group = 20. Amount of poly C or poly I injected intravenously 6 h before first 'vaccine' dose = 4o0 #g. First vaccine dose and second dose I4 days later were both equal to 3oo x LDx00 before inactivation. Virus dose 2I days after first 'vaccine' dose = 5 x LD100.
X2inf. = logrank comparisons with the infected control. X2v = logrank comparisons with the double 'vaccine' control. Value of x/t x lO 2 with X 2 comparisons shown in parentheses.
Direct evidence that the polynucleotides do not stimulate clearance of virus particles
We first found that administration of 4oo/zg poly C or poly I 6 h before vaccination of LACA mice does not affect protection against 2oo × LD100 EMC 14 days later. Approx. 5o ~ of the mice were protected in all groups (between t I and 14 mice out of 2o) but the vaccine dose was such that before inactivation it titred at IO × LD100 and the number of virus particles administered was therefore vastly greater than normally used to infect mice. This may have overloaded any possible mechanism whereby the virus is cleared and we therefore examined the effect of polynucleotide treatment on the ability of two low doses of the EMC 'vaccine' to protect mice against a challenge of virulent EMC 7 days after the second dose of'vaccine'.
We determined a dose of inactivated EMC (' vaccine') that was not protective in a single dose 7 days before challenge by 5 × LD100 virulent EMC but which did give significant protection when two equal doses were given 14 days apart, the second dose being 7 days before the virus challenge. This dose of 'vaccine' corresponded to approx. 3oo × LD100 before inactivation and would therefore have contained only slightly more virus particles than normally used to infect mice and this should not have overloaded any mechanism which clears the virus. We then examined the effect of poly C or poly I, given 6 h before the first 'vaccine' dose, on the degree of protection against infection obtained 7 days after the second dose of'vaccine'. The results, in Table 7 , show that the polynucleotide treatments do not affect the degree of protection obtained by the two 'vaccine' treatments. We therefore conclude that the polynucleotide treatments do not cause clearance of the virus particles in the first 'vaccine' dose and they are therefore unlikely to exert their anti-viral effect by such a mechanism.
The assay for virus clearance used here is based on an antibody response. It is therefore to be understood that we have only demonstrated that the polynucleotide treatments do not cause clearance of virus from immunologically responsive regions of mice.
DISCUSSION
Serum obtained 2, 4 or ~6 h after infection of mice that have been treated with poly C or poly I, 6 h before infection, does not protect other mice against EMC (Table I) , indicating that the polynucleotide treatment does not ' prime' the interferon response of EMC infection itself. Absence of detectable serum interferon in mice treated with poly C or poly I and infected with EMC could occur simply because the interferon is produced only within infected tissues. Such 'priming' by poly C or poly I of non-circulating tissue interferon is difficult to refute. However, EMC virus infection appears to cause interferon production in cells other than those of the haemopoietic system while poty I: C appears to cause production of interferon in macrophages (Jullien et al. ~ 974) . A polynucleotide that' primes' interferon production must, presumably, do so by acting on the same cells as those which produce the interferon. We have demonstrated that neither poly C nor poly I prime interferon induced by poly I : C treatment (Table 2) . Such interferon is known to circulate and these observations support the conclusion that neither poly C nor poly I 'prime' interferon production to levels at which mice are protected.
Synthetic polynucleotides have been implicated in immune responses as adjuvants (Schmidtke & Johnson, r970 and antigens have been found associated with naturally formed RNA in macrophages in particularly antigenic forms (Askonas & Rhodes, I965) . However, treatment of mice with poly C or poly I would not seem to involve such immune responses to EMC virus since mice that survive infection as a result of the polynucleotide treatment show no protection against re-infection and the immunosuppressive agent, cytosine arabinoside, does not suppress the ability of the polynucleotides to protect mice. The possibility of a stimulation of IgM mediated protection against infection seems unlikely from the serum transfer experiments reported here (Table 3) .
There is considerable evidence that macrophages form a major barrier to virus infections in vivo (Allison, ~974) . Our inability to protect mice treated with silica, which is known to be specifically cytotoxic for macrophages (Allison et al. I966) , suggests that macrophages are involved in the protective effect of poly C and poly I. These polynucleotides have not shown any protective effect against EMC infection in suckling mice up to 3 weeks of age (our unpublished results) indicating that the single-stranded polynucleotides require mature macrophages to be effective. Treatment of mice with an EMC 'vaccine' on two occasions 14 days apart at doses that alone are non-protective, caused protection against challenge by EMC virus 2I days after the first 'vaccine' treatment even if the first 'vaccine' treatment was preceded by poly C or poly I treatment (Table 7) . This indicates that the polynucleotide treatment does not simply stimulate a mechanism that causes virus particles to be eliminated from the mouse but that virus particles are retained, at least in immunologically reactive regions of the mouse.
While silica treatment is specifically cytotoxic for macrophages it also causes proliferation and migration of macrophages so that replication of lactic dehydrogenase virus is not decreased but increased by such treatment (Du Buy, I975). These observations would only cast doubt on the involvement of macrophages in the anti-viral effects of poly I and poly C if silica treatment had not abolished protection. Nevertheless, we are unable as yet to say whether the polynucleotides limit some adverse macrophage activity or promote some beneficial activity.
It has been suggested that macrophages are involved in limiting infection of adult mice by viruses such as Coxsackie B-3 because they can eliminate complexes of virus and antibody in the presence of sufficient complement even when the antibody is not one that can neutralize the virus (Rager-Zisman & Allison, 2973). Moreover, Daniels et al. ~97o have demonstrated the efficacy of purified components of complement to neutralize herpes virus with IgM in this way. Although we have not assayed non-neutralizing antibodies to EMC in treated mice or complement levels after polynucleotide treatment, we do not believe that these factors are involved in protection by poly C or poly I for the following reasons. The susceptibility to re-infection after 24 days of mice that survive EMC infection after poly I or poly C treatment demonstrates the absence at this time of the antibodies or elevated complement levels required to sensitize EMC to neutralization. Also, the inability of serum from mice, 2 or 3 days after infection and polynucleotide treatment, to protect other mice against EMC infection shows the absence, at these times, of the components necessary for clearance of virus by macrophages. Finally, the lack of an effect of poly C or poly I treatment on protection by vaccination (Table 7) shows, directly, that virus particles are not in fact cleared from the mouse as a result of the polynucleotide treatment.
The silica treatment experiments indicating that macrophages are involved in protection of mice against EMC by poly I or poly C and the data showing that immune systems are not involved suggests at least three other mechanisms whereby the polynucleotides could be anti-viral:
(I) EMC virus initially replicates in macrophages and these cells may accumulate singlestranded polynucleotides more efficiently than other cells so that silica treatment abolishes the primary target cells of EMC virus infection and causes other cells to be infected which accumulate such polynucleotides rather poorly. Silica treatment does in fact cause the mean time of death of infected mice to occur about 24 h earlier. We suggest in this case that in macrophages poly I and poly C directly inhibit replication of the virus perhaps because they act as competitive inhibitors of homopolynucleotide tracts in virus + or -strand RNA in the manner previously suggested (Stebbing et al. 2976) . Macrophages and similar cells are in fact knownto accumulate viruses rapidly from the blood stream (Mims, 2964) and also support the replication of several viruses including EMC virus and Mengo virus (Allison, 2974; Eustatia et al. 2972 ) .
(2) Protection of mice by poly I or poly C treatment occurs only because of an additional independent macrophage mediated mechanism such that neither mechanism None is protective.
(3) Some direct anti-viral macrophage activity may be stimulated by poly I or poly C treatment or an adverse activity abrogated. In this case silica treatment abolishes protection by poly I or poly C because it destroys the population of macrophages that have these properties. Possible anti-viral activities activated by poly I or poly C are a direct cytotoxic effect on virus infected cells in the manner that other compounds have been shown to The existence of such anti-viral macrophage activities in relation to polynucleotide treatments and the uptake of single-stranded homopolynucleotides by macrophages and other cells are currently being investigated.
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